Research image darker c2.jpg

Accelerating the development of advanced diagnostic tools and effective treatments for systemic amyloidosis through collaboration and innovation


Transform the Research Landscape


The Amyloidosis Research Consortium has been established to address critical needs in clinical trials and related research for the underserved group of systemic amyloid diseases. 

ARC is addressing the urgent, unmet medical needs in amyloidosis.

Screen Shot 2017-07-15 at 2.56.03 PM.png

Rare, Underserved and Underdiagnosed


Amyloidosis is a disorder caused by proteins that possess abnormal conformational features leading them to aggregate and infiltrate tissues in the form of amyloid fibrils. Systemic amyloidosis is a disease that can damage the heart, kidneys, liver, soft tissue and nervous system, resulting in multi-organ failure and death. 

Awareness and understanding of these diseases is the first step to delivering better outcomes for patients.

Screen Shot 2016-04-26 300.jpg

Take Action; Participate in our hATTR Survey


ARC is looking for hATTR patients and caregivers to take part in a survey about your views on hereditary ATTR (hATTR) treatment. The information we collect from the surveys will enable us to make a strong case to regulatory bodies and companies who are researching drugs about the value of new treatments to the hATTR community. Your participation will play an important role in shaping future treatments for hATTR.
We have created two surveys, one for patients and one for caregivers:


Deliver Actionable Solutions for Patients


As a patient led organization ARC has firsthand knowledge of how amyloidosis affects our community. We engage scientists, policymakers and government regulators as partners in our efforts to breakdown barriers to research and drug development. 

Scientific progress is maximized when supported by sound public policy and advocacy.